Related Experiment Video

Updated: Oct 3, 2026

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43
06:06

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43

Published on: September 11, 2020

[Streptococcus pneumoniae: lack of emergence of pristinamycin resistance]

P Weber1

  • 1Laboratoire de biologie médicale BIO VSM, 10, rue de la Gare, 77360 Vaires-sur-Marne, France. pweber.biovsm@wanadoo.fr

Pathologie-Biologie
|January 5, 2002
PubMed

Insights

Recent studies show Streptococcus pneumoniae remains susceptible to pristinamycin, contrary to earlier findings. In vitro activity of this antibiotic is consistent, even with resistant strains, highlighting reliable susceptibility testing methods.

Area of Science:

  • Microbiology
  • Antimicrobial Resistance
  • Pharmacology

Context:

  • Emergence of antibiotic resistance is a significant global health concern.
  • Streptococcus pneumoniae is a major cause of bacterial infections.
  • Pristinamycin is an antibiotic used to treat bacterial infections.

Purpose:

  • To evaluate the current susceptibility of clinical isolates of Streptococcus pneumoniae to pristinamycin.
  • To investigate discrepancies in previous findings regarding pristinamycin resistance.
  • To assess the in vitro activity of pristinamycin against S. pneumoniae over time.

Summary:

  • Recent studies using reference susceptibility testing methods have not confirmed earlier reports of emerging pristinamycin resistance in Streptococcus pneumoniae.
  • Discrepancies in older studies may be attributed to specific testing methodologies, inoculum size, or altered susceptibility breakpoints.
  • Excellent correlation exists between reference methods and commercial liquid-based testing for S. pneumoniae susceptibility.
  • Despite prolonged selective pressure, pristinamycin maintains consistent in vitro activity against S. pneumoniae clinical isolates.

Impact:

  • Confirms the continued efficacy of pristinamycin against Streptococcus pneumoniae.
  • Highlights the importance of standardized and validated susceptibility testing methods.
  • Provides evidence supporting the use of pristinamycin in clinical settings for susceptible S. pneumoniae infections.

Related Concept Videos

Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...